STOCK TITAN

Calliditas Therapeutics to Attend Conferences in April

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) announces its participation in key investor and industry conferences in April 2024, with top management presenting at various panels and offering one-on-one meetings. The company aims to showcase its expertise and engage with stakeholders.
Positive
  • None.
Negative
  • None.

STOCKHOLM, April 9, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Van Lanschot Kempen Life Sciences Conference Amsterdam, Tuesday, April 16, 2024. Renée Aguiar-Lucander, CEO, will be available for one-on-one meetings.

World Orphan Drug Congress, Thursday, April 25, 2024, in Boston, MA. Maria Törnsén, President North America, will be moderating a panel, entitled "Partnering in the rare disease space - industry perspective".

LSX World Congress, Monday, April 29, 2024, in London. Maria Törnsén, President North America, will participate in a panel discussion entitled "Commercial Models of The Future and How the Biopharma Launch Landscape Is Changing: Expert Panel Discussion".

The same day, Renée Aguiar-Lucander, CEO, will participate in a panel discussion entitled "The Inflation Reduction Act and its Potential Impact on EU Biotech & Pharma Companies: Demystifying the Future".

Additionally, Calliditas' Group General Counsel, Brian Gorman, will participate in a panel discussion entitled "Importance of IP Due-Diligence in Deals Within the US".

One-on-one meetings with management will be available.

CONTACT:

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel : +46 76 403 35 43, Email : asa.hillsten@calliditas.com

The information was sent for publication, through the agency of the contact persons set out above, on April 9, 2023, at 13.00 p.m. CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/calliditas-therapeutics/r/calliditas-therapeutics-to-attend-conferences-in-april,c3958630

The following files are available for download:

https://mb.cision.com/Main/16574/3958630/2719451.pdf

CALT -- April Events_ENG

Cision View original content:https://www.prnewswire.com/news-releases/calliditas-therapeutics-to-attend-conferences-in-april-302111671.html

SOURCE Calliditas Therapeutics

Calliditas Therapeutics AB (CALT) will attend Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 16, World Orphan Drug Congress in Boston on April 25, and LSX World Congress in London on April 29, 2024.

Renée Aguiar-Lucander, CEO, and Maria Törnsén, President North America, will be representing Calliditas at the conferences, along with Brian Gorman, Group General Counsel.

The panels will cover areas such as partnering in the rare disease space, commercial models of the future in biopharma, potential impact of the Inflation Reduction Act on EU companies, and the importance of IP due-diligence in deals within the US.

Stakeholders can participate in one-on-one meetings with Calliditas' management to discuss the company's strategies and future plans.

For further information, stakeholders can contact Åsa Hillsten, Head of IR & Sustainability at Calliditas, via phone at +46 76 403 35 43 or email at asa.hillsten@calliditas.com.
Calliditas Therapeutics AB American Depositary Shares

NASDAQ:CALT

CALT Rankings

CALT Latest News

CALT Stock Data

500.58M
37.48M
3.18%
0.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Stockholm

About CALT

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.